| Trial ID: | L0075 |
| Source ID: | NCT02244944
|
| Associated Drug: |
Ezetimibe
|
| Title: |
Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD
|
| Acronym: |
--
|
| Status: |
Terminated
|
| Study Results: |
Has Results
|
| Results: |
https://ClinicalTrials.gov/show/NCT02244944/results
|
| Conditions: |
Nonalcoholic Fatty Liver Disease (NAFLD)
|
| Interventions: |
Drug: EZ-Urso combination therapy
|
| Outcome Measures: |
Reduction in Serum Alanine Transaminase (ALT)|Increase in Plasma Lathosterol|Reduction in Hepatic Fat Fraction
|
| Sponsor/Collaborators: |
Gregory Graf, PhD|University of Kentucky
|
| Gender: |
All
|
| Age: |
18 Years to 75 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 2
|
| Enrollment: |
2
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
|
| Start Date: |
September 2014
|
| Completion Date: |
September 2015
|
| Results First Posted: |
February 7, 2018
|
| Last Update Posted: |
February 7, 2018
|
| Locations: |
University of Kentucky Medical Center, Lexington, Kentucky, United States
|
| URL: |
https://ClinicalTrials.gov/show/NCT02244944
|
